Arachidonic Acid is a 20‑carbon omega‑6 polyunsaturated fatty acid (20:4, n‑6) that is classified among long‑chain polyunsaturated fatty acids. It is released from membrane phospholipids by phospholipase enzymes and converted by cyclooxygenases, lipoxygenases, and cytochrome P450 enzymes into a family of eicosanoids and related mediators. Historically, AA gained clinical research attention as lipid biochemistry and eicosanoid signaling were mapped in the mid‑20th century. Its core functions include maintaining membrane fluidity, serving as a substrate for signaling molecules that regulate immune and vascular responses, and participating in cell‑cell communication and platelet function.

Higher circulating or membrane AA levels are often associated with increased substrate availability for pro‑inflammatory and vasoactive signaling pathways, and may reflect higher dietary omega‑6 intake, shifts in metabolism, or genetic variation in fatty‑acid processing. Elevated AA is best interpreted alongside omega‑3 markers (e.g., EPA/DHA) and functional ratios such as AA/EPA to judge overall signaling balance. Lower AA levels can indicate limited substrate for normal eicosanoid production, altered membrane composition, poor dietary intake of precursor fatty acids, or metabolic/genetic factors reducing synthesis or incorporation. Low AA should also be viewed in the context of the full fatty‑acid profile, clinical history, and nutrient‑processing genetics for accurate interpretation.

Nutrient Zoomer includes AA to evaluate omega‑6 status, inflammatory signaling potential, and fatty‑acid balance relative to omega‑3s. Measuring AA alongside other fatty acids and nutrient‑related genes helps providers identify patterns in lipid metabolism and tailor personalized nutrition strategies based on an individual's biochemical and genetic context.